Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures-Reference-Cited by-同舟云学术

Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures

Published:2021-12-24 Issue: Volume: Page:1-8
ISSN:2167-8421
Container-title:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
language:en
Short-container-title:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Author:

Bakers Jaap N.E.¹²³,de Jongh Adriaan D.¹,Bunte Tommy M.¹,Kendall Lindsay⁴,Han Steve S.⁵,Epstein Noam⁶,Lavrov Arseniy⁷,Beelen Anita²³,Visser-Meily Johanna M.A.²³,van den Berg Leonard H.¹,van Eijk Ruben P. A.¹⁸

Affiliation:

1. Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands

2. Centre of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Centre, University Medical Centre Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the Netherlands

3. Department of Rehabilitation, Physical Therapy Science & Sports, UMC Utrecht Brain Centre, University Medical Centre Utrecht, the Netherlands

4. Biostatistics, GlaxoSmithKline R&D, Stevenage, UK

5. Neurosciences, Takeda Pharmaceuticals, Cambridge, USA

6. Discovery Medicine, GlaxoSmithKline R&D, Upper Providence, USA

7. Clinical Development, Novartis Gene Therapies, Cambridge, UK, and

8. Biostatistics & Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands

Funder

Netherlands ALS foundation

Publisher

Informa UK Limited

Subject

Neurology (clinical),Neurology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21678421.2021.2016838

Reference22 articles.

1. Amyotrophic lateral sclerosis

2. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis

3. Food Drug Administration Center for Drugs Evaluation Research. Guidance for industry: amyotrophic lateral sclerosis: developing drugs for treatment 2019 [Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry.

4. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS) 2016 [Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf.

5. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current neuroprotective therapies and future prospects for motor neuron disease;International Review of Neurobiology;2024

2. Identifying amyotrophic lateral sclerosis through interactions with an internet search engine;Muscle & Nerve;2023-10-25

3. At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis;Nature Communications;2023-08-21

4. Consumer-grade wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis;2023-03-30

5. Clinical Profiles and Patterns of Neurodegeneration in Amyotrophic Lateral Sclerosis: A Cluster-Based Approach Based on MR Imaging Metrics;American Journal of Neuroradiology;2023-03-23